Lincoln Educational Services Corporation announced it will release its third quarter financial results on November 9, 2026, with a conference call scheduled at 10:30 a.m. Eastern time to discuss the results. The company will issue a news release before 9:30 a.m. that day. Investors and interested parties can access the live webcast via Lincoln's website or register for teleconference access. Lincoln is a leading provider of career-oriented post-secondary education with 23 campuses across 12 states, specializing in skilled trades, automotive, health sciences, and IT programs.
Lincoln Educational Services Corporation news is provided here with Pluang's market context for Consumer Cyclical stocks as of Oct 19, 2026 19:41 WIB. Of 134 priced Consumer Cyclical-sector US stocks on Pluang, 63 rose and 51 fell today. Notable movers include ATER at USD 0.57 (+1.60%), GLBE at USD 39.41 (+1.52%), and BBWI at USD 20.44 (+1.49%).
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
